INITIATIVES
Global Regulatory Review and Outreach Workstream
Workstream Objectives
-
Stay abreast of regulatory developments for OINDPs.
-
Understand requirements for OINDPs in emerging markets.
-
Engage in outreach to regulatory agencies, pharmacopeias, and other standard-setting bodies worldwide, as appropriate.
-
Monitor and address, as appropriate, environmental and sustainability priorities.
Working Groups
External Outreach Workstream
Workstream Objectives
-
Grow and evolve membership to ensure IPAC-RS is equipped to address current and future challenges.
-
Develop and implement visibility and outreach strategies to achieve growth goals.
-
Advance the science and scientific discourse between IPAC-RS and external stakeholders in areas of common interest.
-
Collaborate with other trade groups on relevant issues.
-
Increase public visibility of IPAC-RS advocacy, technical work, and subject matter expertise.
Working Groups
-
Membership Committee
-
Roundtables, webinar, and conferences with key stakeholders and thought leaders
-
Collaborations with other organizations, as appropriate (e.g., ISAM, RDD, DDL, EPAG, AAPS, IPAC, and PQRI)
Product Development Workstream
Workstream Objectives
-
Monitor, assess, and respond to regulatory developments related to chemisty, manufacturing, and controls (CMC) and product development for small/synthetic molecules as well as large molecules and biologics.
-
Develop improved approaches, “best practices” and other recommendations for CMC and product development analytical testing, formulation, manufacturing, stability, material selection, product characterization, and other topics.
Working Groups and Knowledge Networks
-
Aerodynamic Particle Size Distribution (APSD) Testing/Cascade Impaction (CI)
-
Product Quality Demonstration Strategy (PQDS) Knowledge Network
-
Inhaled and Nasal Biologics Working Group (see information from Sept 2024 workshop here)
Delivery Systems Workstream
Workstream Objectives
-
Develop and share industry practices and monitor regulatory developments related to OINDP devices and device-patient interface, and container-closure systems.
-
Develop and promulgate device-related recommendations for OINDP industry, device manufacturers, regulators, health-care providers, patients and other potential stakeholders.
-
Explore and collaboratively address challenges related to nasal delivery systems.
-
Discuss and publish considerations for materials selection and quality with new propellants.
-
Examine regulatory requirements related to change management, starting with Europe and thereafter in the US and later ini other world regions. Promote streamlining and harmonization of requirements.
Working Groups
-
Materials and Propellants Quality Considerations
-
Change Management
-
Nasal WG and subteams